Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 16 of the 18 references it cites were found in a registry or an index, and 2 are not checked yet.

Sarcopenia: revised European consensus on definition and diagnosis

Open access
Cruz-Jentoft, Alfonso J, Bahat, Gϋlistan, Bauer, Jϋrgen, Boirie, Yves, Bruyère, Olivier, Cederholm, Tommy, Cooper, Cyrus, Landi, Francesco, Rolland, Yves, Sayer, Avan Aihie, Schneider, Stéphane M, Sieber, Cornel C, Topinkova, Eva, Vandewoude, Maurits, Visser, Marjolein, Zamboni, Mauro, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2 · 2019 · Age and Ageing

Abstract

doi: 10.1093/ageing/afy169 In the original version of the above paper there was an error in Table 3, which shows the recommended cut-off points for ASM/height2 in women. The cut-off point was given as <6.0 kg/m2, but the correct value is <5.5 kg/m2. This has now been corrected online. The authors wish to apologise for this error.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ageing/afz046

Cites

0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Sarcopenia: EWGSOP2 algorithm for case- fi nding, making a diagnosis and quantifying severity in practice. The steps of the pathway are represented as Find-Assess-Con fi rmSeverity or F-A-C-S. * Consider other reasons for low muscle strength (e.g. depression, sroke, balance disorders, peripheral vascular disorders).
Figure 1 Sarcopenia: EWGSOP2 algorithm for case- fi nding, making a diagnosis and quantifying severity in practice. The steps of the pathway are represented as Find-Assess-Con fi rmSeverity or F-A-C-S. * Consider other reasons for low muscle strength (e.g. depression, sroke, balance disorders, peripheral vascular disorders).CC-BY-NC · From the PDF
Image 2
CC-BY-NC · From the PDF
Figure 3 Muscle strength and the life course. To prevent or delay sarcopenia development, maximise muscle in youth and young adulthood, maintain muscle in middle age and minimise loss in older age
Figure 3 Muscle strength and the life course. To prevent or delay sarcopenia development, maximise muscle in youth and young adulthood, maintain muscle in middle age and minimise loss in older ageCC-BY-NC · From the PDF
Figure 4 Factors that cause and worsen muscle quantity and quality, sarcopenia, are categorised as primary (ageing) and secondary (disease, inactivity , and poor nutrition). Because a wide range of factors contribute to sarcopenia development, numerous muscle changes seem possible when these multiple factors interact.
Figure 4 Factors that cause and worsen muscle quantity and quality, sarcopenia, are categorised as primary (ageing) and secondary (disease, inactivity , and poor nutrition). Because a wide range of factors contribute to sarcopenia development, numerous muscle changes seem possible when these multiple factors interact.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Part of this paper’s reference list could not be split into single entries.

Research works printed but not linked: 82

  1. Morley JE, Abbatecola AM, Argiles JM et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011; 12: 403-9.
  2. Studenski SA, Peters KW, Alley DE et al. The FNIH sarco- penia project: rationale, study description, conference recom- mendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014; 69: 547-58.
  3. Chen LK, Liu LK, Woo J et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc 2014; 15: 95-101.
  4. Argiles JM, Campos N, Lopez-Pedrosa JM et al. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J Am Med Dir Assoc 2016; 17: 789-96.
  5. Vellas B, Fielding RA, Bens C et al. Implications of ICD-10 for sarcopenia clinical practice and clinical trials: report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 2018; 7: 2-9.
  6. Mijnarends DM, Luiking YC, Halfens RJG et al. Muscle, health and costs: a glance at their relationship. J Nutr Health Aging 2018; 22: 766-73.
  7. Bischoff-Ferrari HA, Orav JE, Kanis JA et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int 2015; 26: 2793-802.
  8. Schaap LA, van Schoor NM, Lips P et al. Associations of sar- copenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci 2018; 73: 1199-204.
  9. Malmstrom TK, Miller DK, Simonsick EM et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016; 7: 28-36.
  10. Bahat G, Ilhan B. Sarcopenia and the cardiometabolic syn- drome: a narrative review. Eur Geriatr Med 2016; 6: 220-23.
  11. Bone AE, Hepgul N, Kon S et al. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis 2017; 14: 85-99.
  12. Chang KV, Hsu TH, Wu WT et al. Association between sarco- penia and cognitive impairment: a systematic review and meta- analysis. J Am Med Dir Assoc 2016; 17: 1164.e7-64.e15.
  13. Beaudart C, Biver E, Reginster JY et al. Validation of the SarQoL(R), a specific health-related quality of life question- naire for Sarcopenia. J Cachexia Sarcopenia Muscle 2017; 8: 238-44.
  14. Dos Santos L, Cyrino ES, Antunes M et al. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle 2017; 8: 245-50.
  15. Steffl M, Bohannon RW, Sontakova L et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging 2017; 12: 835-45.
  16. De Buyser SL, Petrovic M, Taes YE et al. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing 2016; 45: 602-8.
  17. Cawthon PM, Lui LY, Taylor BC et al. Clinical definitions of sarcopenia and risk of hospitalization in community-dwelling older men: the osteoporotic fractures in men study. J Gerontol A Biol Sci Med Sci 2017; 72: 1383-89.
  18. Antunes AC, Araujo DA, Verissimo MT et al. Sarcopenia and hospitalisation costs in older adults: a cross-sectional study. Nutr Diet 2017; 74: 46-50.
  19. Steffl M, Sima J, Shiells K et al. The increase in health care costs associated with muscle weakness in older people with- out long-term illnesses in the Czech Republic: results from the Survey of Health, Ageing and Retirement in Europe (SHARE). Clin Interv Aging 2017; 12: 2003-07.
  20. Sousa AS, Guerra RS, Fonseca I et al. Financial impact of sar- copenia on hospitalization costs. Eur J Clin Nutr 2016; 70: 1046-51.
  21. Sayer AA, Syddall H, Martin H et al. The developmental ori- gins of sarcopenia. J Nutr Health Aging 2008; 12: 427-32.
  22. Dodds RM, Syddall HE, Cooper R et al. Grip strength across the life course: normative data from twelve British studies. PLoS One 2014; 9: e113637.
  23. Sayer AA, Syddall HE, Gilbody HJ et al. Does sarcopenia ori- ginate in early life? Findings from the Hertfordshire cohort study. J Gerontol A Biol Sci Med Sci 2004; 59: M930-4.
  24. Ibrahim K, May C, Patel HP et al. A feasibility study of implementing grip strength measurement into routine hos- pital practice (GRImP): study protocol. Pilot Feasibility Stud 2016; 2: 27.
  25. Leong DP, Teo KK, Rangarajan S et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015; 386: 266-73.
  26. Alley DE, Shardell MD, Peters KW et al. Grip strength cut- points for the identification of clinically relevant weakness. J Gerontol A Biol Sci Med Sci 2014; 69: 559-66.
  27. Buckinx F, Landi F, Cesari M et al. Pitfalls in the measure- ment of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle 2018; 9: 269-78.
  28. Masanes F, Rojano ILX, Salva A et al. Cut-off points for muscle mass-not grip strength or gait speed-determine variations in sarcopenia prevalence. J Nutr Health Aging 2017; 21: 825-29.
  29. McGregor RA, Cameron-Smith D, Poppitt SD. It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. Longev Healthspan 2014; 3: 9.
  30. Trevino-Aguirre E, Lopez-Teros T, Gutierrez-Robledo L et al. Availability and use of dual energy X-ray absorptiometry (DXA) and bio-impedance analysis (BIA) for the evaluation of sarcopenia by Belgian and Latin American geriatricians. J Cachexia Sarcopenia Muscle 2014; 5: 79-81.
  31. Mijnarends DM, Meijers JM, Halfens RJ et al. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. J Am Med Dir Assoc 2013; 14: 170-8.
  32. Roberts HC, Denison HJ, Martin HJ et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 2011; 40: 423-9.
  33. Schweitzer L, Geisler C, Pourhassan M et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? Am J Clin Nutr 2015; 102: 58-65.
  34. Shen W, Punyanitya M, Wang Z et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004; 97: 2333-8.
  35. Sergi G, De Rui M, Stubbs B et al. Measurement of lean body mass using bioelectrical impedance analysis: a consideration of the pros and cons. Aging Clin Exp Res 2017; 29: 591-97.
  36. Maden-Wilkinson TM, Degens H, Jones DA et al. Comparison of MRI and DXA to measure muscle size and age-related atrophy in thigh muscles. J Musculoskelet Neuronal Interact 2013; 13: 320-8.
  37. Heymsfield SB, Smith R, Aulet M et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr 1990; 52: 214-8.
  38. Kim J, Wang Z, Heymsfield SB et al. Total-body skeletal mus- cle mass: estimation by a new dual-energy X-ray absorpti- ometry method. Am J Clin Nutr 2002; 76: 378-83.
  39. Lee SJ, Janssen I, Heymsfield SB et al. Relation between whole-body and regional measures of human skeletal muscle. Am J Clin Nutr 2004; 80: 1215-21.
  40. Derstine BA, Holcombe SA, Ross BE et al. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 mea- surements in a healthy US population. Sci Rep 2018; 8: 11369.
  41. Goodpaster BH, Kelley DE, Thaete FL et al. Skeletal muscle attenuation determined by computed tomography is asso- ciated with skeletal muscle lipid content. J Appl Physiol (1985) 2000; 89: 104-10.
  42. Reinders I, Murphy RA, Brouwer IA et al. Muscle quality and myosteatosis: novel associations with mortality risk: the Age, Gene/Environment Susceptibility (AGES)-Reykjavik study. Am J Epidemiol 2016; 183: 53-60.
  43. Grimm A, Meyer H, Nickel MD et al. Evaluation of 2-point, 3-point, and 6-point Dixon magnetic resonance imaging with flexible echo timing for muscle fat quantification. Eur J Radiol 2018; 103: 57-64.
  44. Distefano G, Standley RA, Zhang X et al. Physical activity unveils the relationship between mitochondrial energetics, muscle quality, and physical function in older adults. J Cachexia Sarcopenia Muscle 2018; 9: 279-94.
  45. Ruan XY, Gallagher D, Harris T et al. Estimating whole body intermuscular adipose tissue from single cross-sectional magnetic resonance images. J Appl Physiol (1985) 2007; 102: 748-54.
  46. Woo J, Leung J, Morley JE. Defining sarcopenia in terms of incident adverse outcomes. J Am Med Dir Assoc 2015; 16: 247-52.
  47. Bahat G, Yilmaz O, Oren M et al. Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodo- logical report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. Eur Geriatr Med 2018; 9: 23-8.
  48. Locquet M, Beaudart C, Reginster JY et al. Comparison of the performance of five screening methods for sarcopenia. Clin Epidemiol 2018; 10: 71-82.
  49. Rossi AP, Fantin F, Micciolo R et al. Identifying sarcopenia in acute care setting patients. J Am Med Dir Assoc 2014; 15: 303.e7-12.
  50. Steiber N. Strong or weak handgrip? Normative reference values for the German population across the life course stratified by sex, age, and body height. PLoS One 2016; 11: e0163917.
  51. Beaudart C, McCloskey E, Bruyere O et al. Sarcopenia in dai- ly practice: assessment and management. BMC Geriatr 2016; 16: 170.
  52. Sipers WM, Verdijk LB, Sipers SJ et al. The Martin vigori- meter represents a reliable and more practical tool than the Jamar dynamometer to assess handgrip strength in the geriat- ric patient. J Am Med Dir Assoc 2016; 17: 466.e1-7.
  53. Francis P, Toomey C, Mc Cormack W et al. Measurement of maximal isometric torque and muscle quality of the knee extensors and flexors in healthy 50-to 70-year-old women. Clin Physiol Funct Imaging 2017; 37: 448-55.
  54. Cesari M, Kritchevsky SB, Newman AB et al. Added value of physical performance measures in predicting adverse health- related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc 2009; 57: 251-9.
  55. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport 1999; 70: 113-9.
  56. Cooper C, Fielding R, Visser M et al. Tools in the assessment of sarcopenia. Calcif Tissue Int 2013; 93: 201-10.
  57. Cawthon PM, Peters KW, Shardell MD et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci 2014; 69: 567-75.
  58. Hull H, He Q, Thornton J et al. iDXA, Prodigy, and DPXL dual-energy X-ray absorptiometry whole-body scans: a cross- calibration study. J Clin Densitom 2009; 12: 95-102.
  59. Kim KM, Jang HC, Lim S. Differences among skeletal mus- cle mass indices derived from height-, weight-, and body mass index-adjusted models in assessing sarcopenia. Korean J Intern Med 2016; 31: 643-50.
  60. Kyle UG, Genton L, Hans D et al. Validation of a bioelec- trical impedance analysis equation to predict appendicular skeletal muscle mass (ASMM). Clin Nutr 2003; 22: 537-43.
  61. Sergi G, De Rui M, Veronese N et al. Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. Clin Nutr 2015; 34: 667-73.
  62. Gonzalez MC, Heymsfield SB. Bioelectrical impedance ana- lysis for diagnosing sarcopenia and cachexia: what are we really estimating? J Cachexia Sarcopenia Muscle 2017; 8: 187-89.
  63. Yu SC, Powell A, Khow KS et al. The performance of five bioelectrical impedance analysis prediction equations against dual X-ray absorptiometry in estimating appendicular skeletal muscle mass in an Adult Australian Population. Nutrients 2016; 8: 189.
  64. Reiss J, Iglseder B, Kreutzer M et al. Case finding for sarco- penia in geriatric inpatients: performance of bioimpedance analysis in comparison to dual X-ray absorptiometry. BMC Geriatr 2016; 16: 52.
  65. Tosato M, Marzetti E, Cesari M et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. Aging Clin Exp Res 2017; 29: 19-27.
  66. Landi F, Onder G, Russo A et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr 2014; 33: 539-44.
  67. Bruyere O, Beaudart C, Reginster J-V et al. Assessment of muscle mass, muscle strength and physical performance in clinical practice: an international survey. Eur Geriatr Med 2016; 7: 243-46.
  68. Abellan van Kan G, Rolland Y, Andrieu S et al. Gait speed at usual pace as a predictor of adverse outcomes in community- dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging 2009; 13: 881-9.
  69. Peel NM, Kuys SS, Klein K. Gait speed as a measure in geri- atric assessment in clinical settings: a systematic review. J Gerontol A Biol Sci Med Sci 2013; 68: 39-46.
  70. Studenski S, Perera S, Patel K et al. Gait speed and survival in older adults. JAMA 2011; 305: 50-8.
  71. Guralnik JM, Ferrucci L, Pieper CF et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 2000; 55: M221-31.
  72. Maggio M, Ceda GP, Ticinesi A et al. Instrumental and non- instrumental evaluation of 4-meter walking speed in older individuals. PLoS One 2016; 11: e0153583.
  73. Rydwik E, Bergland A, Forsen L et al. Investigation into the reliability and validity of the measurement of elderly people's clinical walking speed: a systematic review. Physiother Theory Pract 2012; 28: 238-56.
  74. Podsiadlo D, Richardson S. The timed 'Up & Go': a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142-8.
  75. Pavasini R, Guralnik J, Brown JC et al. Short physical per- formance battery and all-cause mortality: systematic review and meta-analysis. BMC Med 2016; 14: 215.
  76. Vestergaard S, Patel KV, Bandinelli S et al. Characteristics of 400-meter walk test performance and subsequent mortality in older adults. Rejuvenation Res 2009; 12: 177-84.
  77. Bergland A, Jorgensen L, Emaus N et al. Mobility as a pre- dictor of all-cause mortality in older men and women: 11.8 year follow-up in the Tromso study. BMC Health Serv Res 2017; 17: 22.
  78. Heymsfield SB, Gonzalez MC, Lu J et al. Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc 2015; 74: 355-66.
  79. Fearon K, Strasser F, Anker SD et al. Definition and classifi- cation of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-95.
  80. Kim EY, Kim YS, Park I et al. Prognostic significance of CT- determined sarcopenia in patients with small-cell lung cancer. J Thorac Oncol 2015; 10: 1795-9.
  81. Baracos V, Kazemi-Bajestani SM. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol 2013; 45: 2302-8.
  82. Moisey LL, Mourtzakis M, Cotton BA et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Crit Care 2013; 17: R206.

Cited by

See all 3,803

Metadata

Authors
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., Zamboni, M., & Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), A. T. E. G. F. E.
Affiliations
  • Instituto Ramón y Cajal de Investigación Sanitaria (ES)
  • Istanbul University-Cerrahpaşa (TR)
  • Heidelberg University (DE)
  • University of Liège (BE)
  • Uppsala University (SE)
  • MRC Lifecourse Epidemiology Unit (GB)
  • Università Cattolica del Sacro Cuore (IT)
  • Université de Toulouse (FR)
  • Université Côte d'Azur (FR)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • University of Antwerp (BE)
  • Amsterdam Public Health (NL)
  • University of Verona (IT)
Venue
Age and Ageing
Published
2019-05-13
Volume
48
Issue
4
Pages
601-601
ISSN
  • 0002-0729 (ISSN-L)
  • 1468-2834
OpenAlex
W2981414419
Cited by
3,803
References
0
Citations by year
2026: 1224 · 2025: 588 · 2024: 587 · 2023: 459 · 2022: 350 · 2021: 339 · 2020: 190 · 2019: 62
FWCI
161.38
Type
journal article
Language
en
Open access
Locations
  • Age and Ageing (publishedVersion, cc-by-nc)
  • HAL (submittedVersion, cc-by-nc)
  • Research Publications (Maastricht University) (submittedVersion, cc-by-nc)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by-nc)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
Keywords
sarcopenia, definitions, diagnosis, appendicular skeletal muscle mass, cut-off values, women, European consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sarcopenia: revised European consensus on definition and diagnosis. https://app.cochat.ai/papers/10.1093/ageing/afz046
The paper
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., Zamboni, M., & Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), A. T. E. G. F. E. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. https://doi.org/10.1093/ageing/afz046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.